Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
| Author | |
|---|---|
| Abstract | :
Squamous cell carcinoma of the anal canal (SCCA) is a rare malignancy associated with infection by human papillomavirus (HPV). No consensus treatment approach exists for the treatment of metastatic disease. Because intratumoral HPV oncoproteins upregulate immune checkpoint proteins such as PD-1 to evade immune-mediated cytotoxicity, we did a trial of the anti-PD-1 antibody nivolumab for patients with metastatic SCCA. |
| Year of Publication | :
2017
|
| Journal | :
The Lancet. Oncology
|
| Volume | :
18
|
| Issue | :
4
|
| Number of Pages | :
446-453
|
| ISSN Number | :
1470-2045
|
| URL | :
https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(17)30104-3
|
| DOI | :
10.1016/S1470-2045(17)30104-3
|
| Short Title | :
Lancet Oncol
|
| Download citation |